GSK Purinethol Labeling Should Mention Tests For TPMT Enzyme Activity
• By The Pink Sheet
GlaxoSmithKline's Purinethol (6-mercaptopurine) labeling should mention the availability of tests for TPMT enzyme deficiency but should not specify how and when they should be used, FDA's Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee said at its July 15 meeting
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
Mexico’s drugs regulator will be able to grant quicker drug approvals based on decisions issued by World Health Organization listed authorities and founding ICH members.
Biogen has U-turned on its original decision not to file Qalsody for marketing approval in the UK for treating certain patients with amyotrophic lateral sclerosis. The move appears to have been triggered by a change in the reimbursement pathway agreed for the product.